Trial Profile
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Telaglenastat (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Calithera Biosciences
- 27 Oct 2021 Status changed from active, no longer recruiting to completed.
- 09 Aug 2021 Planned End Date changed from 1 Jun 2021 to 24 Nov 2022.
- 09 Aug 2021 Planned primary completion date changed from 1 Jun 2020 to 24 Nov 2021.